• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RAC 1.55% $1.31

RACE ONCOLOGY LTD - Corporate Spotlight

Race Oncology Limited is an Australia-based precision oncology company with a Phase... Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.More

No Corporate Spotlight currently available.

(20min delay)
Last
$1.31
Change
0.020(1.55%)
Mkt cap ! $217.2M
Open High Low Value Volume
$1.31 $1.31 $1.26 $71.25K 55.65K

Buyers (Bids)

No. Vol. Price($)
1 200 $1.27
 

Sellers (Offers)

Price($) Vol. No.
$1.31 5950 3
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
$1.31
  Change
0.020 ( 2.18 %)
Open High Low Volume
$1.30 $1.31 $1.26 10789
Last updated 15.59pm 26/04/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.